Working to bring novel SH2 inhibitors to those in need
*Recludix has the option to participate in an equal profit-sharing arrangement in the US, which includes certain co-promotion activities
STAT6 inhibitor:
REX-8756
Recludix is pursuing a novel approach to modulate the activity of the JAK/STAT family of pathways by targeting the downstream STAT6 protein through the inhibition of its SH2 domain. Targeting STAT6 with a highly selective inhibitor is expected to provide a more focused biological response than is observed with many JAK family kinase inhibitors. This may result in fewer side effects and the ability to more profoundly inhibit a specific pathway at well-tolerated doses.
REX-8756 is a first-in-class, highly potent, selective, durable, and reversible orthosteric inhibitor of the STAT6 SH2 domain. It has shown complete pathway inhibition and potent efficacy in preclinical models of asthma, acute lung inflammation, and dermatitis. REX-8756 is being advanced in a blinded, placebo-controlled Phase 1 study in healthy volunteers.
BTK inhibitor
Recludix has a program underway to develop a next-generation BTK inhibitor by targeting the SH2 domain instead of the kinase domain, which is the target of other BTK inhibitors. Inhibiting the protein at the SH2 domain is expected to disrupt both access to downstream targets of the kinase and other pro-inflammatory scaffolding functions, which may result in enhanced efficacy and a wider therapeutic window than other BTK inhibitor approaches. Additionally, highly differentiated chemical matter has demonstrated best-in-class in vitro selectivity, conferring potential safety and efficacy advantages.
New target opportunities identified with platform
The opportunity to identify inhibitors of new targets with Recludix’s platform is vast. There are 120 SH2 domains identified in humans, and many targets that are known to play a role in disease pathology have SH2 domains. Additionally, the distinct features of Recludix’s integrated technology platform can be used to drug non-SH2 domain targets.